Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells 4,551 Shares of Stock

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. The trade was a 3.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

UroGen Pharma Price Performance

UroGen Pharma stock traded up $0.14 during trading hours on Tuesday, hitting $11.35. The stock had a trading volume of 106,431 shares, compared to its average volume of 348,812. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a 1-year low of $9.78 and a 1-year high of $20.70. The stock’s fifty day moving average is $11.12 and its two-hundred day moving average is $12.64. The stock has a market capitalization of $266.09 million, a price-to-earnings ratio of -3.61 and a beta of 1.08.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter last year, the business earned ($0.68) earnings per share. As a group, analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

URGN has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Thursday, January 23rd. Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $43.70.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. RTW Investments LP lifted its holdings in UroGen Pharma by 6.5% during the 3rd quarter. RTW Investments LP now owns 3,787,347 shares of the company’s stock worth $48,099,000 after buying an additional 230,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of UroGen Pharma by 1.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company’s stock worth $17,032,000 after purchasing an additional 21,072 shares during the last quarter. State Street Corp lifted its holdings in shares of UroGen Pharma by 5.9% in the 3rd quarter. State Street Corp now owns 769,583 shares of the company’s stock worth $9,774,000 after purchasing an additional 42,907 shares during the last quarter. Geode Capital Management LLC raised its stake in UroGen Pharma by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after acquiring an additional 34,248 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in shares of UroGen Pharma during the 3rd quarter valued at $5,080,000. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.